N@N

ArQule, Inc. to Present at Lazard Capital Markets 7th Annual Healthcare Conference

_{//health-fitness.news-articles.net/content/2010/ .. al-markets-7th-annual-healthcare-conference.html}
^{Published in Health and Fitness on Wednesday, November 10th 2010 at 13:10 GMT by Market Wire}  

WOBURN, Mass.--([ BUSINESS WIRE ])--ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at the Lazard Capital Markets 7th Annual Healthcare Conference on November 17, 2010 at 11:30 a.m.. Eastern Time. The presentation will be web cast live and may be accessed through the investor relations section of the Companya™s website, [ http://www.arqule.com ]. The Lazard conference will be held at the St. Regis Hotel, New York.

About ArQule

ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Companya™s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQulea™s lead product, in Phase 2 and upcoming Phase 3 clinical development, is ARQ 197, an inhibitor of the c-MET receptor tyrosine kinase. The Company is also conducting Phase 1 clinical testing with ARQ 621, designed to inhibit the Eg5 kinesin motor protein. The Companya™s pre-clinical pipeline includes a compound designed to inhibit the B-RAF kinase. ArQulea™s current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIPa"), are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate) for binding to the kinase. The most advanced AKIPa" program is focused on the discovery of inhibitors of fibroblast growth factor receptor (FGFR).